No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IDXX240621C610000
- 1.55
- 0.000.00%
15min DelayTrading May 15 12:54 ET
0.00High0.00Low
0.00Open1.55Pre Close0 Volume24 Open Interest610.00Strike Price0.00Turnover200.06%IV23.53%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry1.55Extrinsic Value100Contract SizeAmericanOptions Type0.0595Delta0.0019Gamma319.40Leverage Ratio-1.5190Theta0.0012Rho18.99Eff Leverage0.0376Vega
Intraday
- 5D
- Daily
News
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $7,600 Today
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 10 years by 11.41% on an annualized basis producing an average annual return of 22.31%. Currently, IDEXX Laboratories has a m
How Is The Market Feeling About IDEXX Laboratories?
IDEXX Laboratories's (NYSE:IDXX) short percent of float has risen 3.44% since its last report. The company recently reported that it has 1.75 million shares sold short, which is 2.71% of all regular s
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
IDEXX Laboratories (NASDAQ:IDXX) has had a rough three months with its share price down 9.0%. But if you pay close attention, you might gather that its strong financials could mean that the stock co
When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Express News | Idexx Laboratories Has Launched Catalyst Pancreatic Lipase Test For Canine And Feline Patients Suspected Of Pancreatitis, It Will Be Available In US And Canada This September, With Global Rollout To Over 70,000 Installed Base Planned In Q4 Of 2024
IDEXX Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst Pancreatic Lipase Test,...
Comments
$IDEXX Laboratories Inc(IDXX.US$ 👀 Here's How Much You Would Have Made Owning
IDEXX Laboratories Stock In The Last 15 Years!
IDEXX Laboratories Stock In The Last 15 Years!
The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.
IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.
Long-term performance of IDEXX shows positive returns despite recent downturn. Market caution and strong momentum warrant closer scrutiny. Nonetheless, investors should note the existent 2 warning signs.
Comment:
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
Read more